On December 14, 2018 RadioMedix Inc reported that it has been selected by the National Cancer Institute (NCI) Small Business Innovation Research Development Center (SBIR) to participate in 2018 Bio Investor Forum (Press release, RadioMedix, DEC 14, 2018, View Source [SID1234532075]). The company received federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services (HHSN261201600015C, HHS261201800048C/75N91018C00048) for the development of radiotherapeutic alpha-emitter labeled agents.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Izabela Tworowska, Chief Science Officer of RadioMedix, presented the corporate overview of the company pipeline at the 2018 Bio Investor Forum held in San Francisco, California. The presentation was sponsored by NCI SBIR Development Center’s Investor Initiatives program. Dr. Tworowska provided an overview of the research and financial growth of the RadioMedix, discussed the company pipeline and the status of the clinical development of radiotheranostic drugs.
"We have been invited to attend the Bio Investor Forum in San Francisco for two consecutive years and we are grateful the NCI SBIR Investor Initiatives for this invitation and also for the feedback on our presentation", said Dr. Tworowska. "It is a great opportunity to attend One-on-One Partnering meetings and gain the interest of the pharmaceutical companies and investors", added Dr. Tworowska.
"RadioMedix’s rich clinical stage pipeline of innovative radiopharmaceuticals makes an attractive case for investors, and large companies, familiar with our space", said Dr. Delpassand, Chairman and CEO of RadioMedix. "Targeted radioligand therapy will be the strongest segment in the field of nuclear medicine and RadioMedix is well-positioned to take advantage of this opportunity", added Dr. Delpassand.